{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:05:54Z","timestamp":1784549154543,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rpth.2026.106654","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:59:59Z","timestamp":1779206399000},"page":"106654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8033-7298","authenticated-orcid":false,"given":"Anniek","family":"Strijdhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien M.","family":"Salet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jente M.","family":"Schoenaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vossa","family":"van der Vegte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.P.","family":"Seijkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf T.","family":"Urbanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106654_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.rpth.2026.106654_bib2","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.rpth.2026.106654_bib3","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2023-187867","article-title":"Risks for venous thromboembolism with immune checkpoint inhibitor therapy","volume":"142","author":"Connors","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106654_bib4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.106654_bib5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1055\/s-0042-1749185","article-title":"Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials","volume":"122","author":"Ma","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106654_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rpth.2026.106654_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cells13040305","article-title":"Interaction between NSCLC cells, CD8(+) T-cells and immune checkpoint inhibitors potentiates coagulation and promotes metabolic remodeling-new cues on CAT-VTE","volume":"13","author":"Freitas-Dias","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.rpth.2026.106654_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102933","article-title":"Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED study","volume":"9","author":"Vladic","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106654_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jcm8060762","article-title":"Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106654_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.rpth.2026.106654_bib11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.rpth.2026.106654_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106654_bib13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtha.2022.12.002","article-title":"Targeting thromboinflammation in antiphospholipid syndrome","volume":"21","author":"Salet","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106654_bib14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3324\/haematol.2018.209536","article-title":"Interleukin-17\/interleukin-21 and interferon-\u03b3 producing T cells specific for \u03b22 glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome","volume":"104","author":"Benagiano","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106654_bib15","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2026.106654_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.873644","article-title":"Preliminary study on the imbalance between Th17 and regulatory T cells in antiphospholipid syndrome","volume":"13","author":"Yan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.rpth.2026.106654_bib17","article-title":"Acquired coagulopathy with immune checkpoint inhibitors: an underrecognized association between inflammation and coagulation","volume":"1","author":"Joseph","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.rpth.2026.106654_bib18","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5","year":"2017"},{"key":"10.1016\/j.rpth.2026.106654_bib19","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106654_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.rpth.2026.106654_bib21","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.jtha.2023.05.024","article-title":"Anti-\u03b22-glycoprotein I and anti-phosphatidylserine\/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C","volume":"21","author":"Noordermeer","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106654_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1075121","article-title":"Application of the thrombin generation assay in patients with antiphospholipid syndrome: a systematic review of the literature","volume":"10","author":"Gehlen","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.rpth.2026.106654_bib23","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rpth.2026.106654_bib24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/jth.12537","article-title":"Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH","volume":"12","author":"Devreese","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106654_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rpth.2026.106654_bib26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/cancers16061226","article-title":"T-cell subtypes and immune signatures in cutaneous immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy","volume":"16","author":"Absmaier-Kijak","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rpth.2026.106654_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.rpth.2026.106654_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2023022276","article-title":"Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development","volume":"143","author":"Mueller-Calleja","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106654_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1445-5994.1991.tb01356.x","article-title":"Antiphospholipid antibodies","volume":"21","author":"McNeil","year":"1991","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.rpth.2026.106654_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-018-0773-x","article-title":"Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant)","volume":"20","author":"Mendoza-Pinto","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rpth.2026.106654_bib31","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.3390\/jcm14103451","article-title":"Exploring the emerging association between immune checkpoint inhibitors and thrombosis","volume":"14","author":"Fawaz","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106654_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926033121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926033121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:22:21Z","timestamp":1784546541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926033121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2475037926033121"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106654","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106654"}}